Hepatitis Is Killing 1.34 Million People a Year. The 2030 Deadline Is Slipping.

The numbers are stubborn. Despite years of coordinated global effort, viral hepatitis killed 1.34 million people in 2024, according to a new World Health Organization report released at the World Hepatitis Summit. Hepatitis B and C together account for 95% of those deaths, and transmission continues even as treatment and prevention tools exist that could, in theory, bring both diseases close to elimination. The gap between what is scientifically possible and what is actually happening tells a story about health systems, funding, and political will that goes well beyond any single disease.

The WHO has set a target to eliminate viral hepatitis as a public health threat by 2030, a goal that requires reducing new infections by 90% and deaths by 65% from 2015 baseline levels. Progress is real but uneven. Coverage of hepatitis B birth-dose vaccines has expanded significantly in many regions, and the advent of highly effective direct-acting antivirals for hepatitis C transformed what was once a near-death sentence into a curable condition in most cases. Yet the people dying in 2024 are largely those who were never diagnosed, never linked to care, or never reached by health systems that remain fragmented, underfunded, or simply absent in the places where the burden is heaviest.

The disease is not evenly distributed. Sub-Saharan Africa and the Western Pacific region carry a disproportionate share of hepatitis B infections, driven partly by mother-to-child transmission at birth, while hepatitis C is heavily concentrated among people who inject drugs and in countries where unsafe medical procedures remain common. These are populations that health systems have historically struggled or failed to prioritize, and that reality is baked into the mortality figures.

What makes hepatitis particularly difficult to eliminate is its silence. Most people infected with hepatitis B or C have no symptoms for years or even decades, meaning they do not seek care, do not get tested, and do not know they are transmitting the virus. By the time liver cirrhosis or hepatocellular carcinoma appears, the window for low-cost intervention has long closed. This biological feature interacts badly with health systems that are reactive rather than preventive, and with screening programs that remain patchy even in middle-income countries.

The economics compound the problem. Generic direct-acting antivirals for hepatitis C can now cost as little as $60 to $200 for a full curative course in low-income countries, a dramatic fall from the tens of thousands of dollars those drugs once commanded. Yet even at those prices, national programs require sustained procurement, diagnostic infrastructure, and trained health workers to deliver treatment at scale. Countries managing simultaneous burdens of HIV, tuberculosis, malaria, and now the lingering aftershocks of COVID-19 face brutal triage decisions about where to direct limited resources. Hepatitis, lacking the political urgency of an acute outbreak, often loses.

Donor financing patterns reinforce this. Global health funding mechanisms like the Global Fund to Fight AIDS, Tuberculosis and Malaria have no hepatitis mandate, and dedicated hepatitis funding from bilateral donors remains thin relative to the disease burden. The WHO report's implicit message is that the architecture of global health financing was not built with hepatitis in mind, and retrofitting it has proven slow.

If the 2030 elimination targets are missed, the consequences are not merely symbolic. Every year of delayed elimination represents hundreds of thousands of preventable deaths and a growing reservoir of chronic infection that will drive liver cancer rates for decades to come. Hepatocellular carcinoma, the most common form of liver cancer, is one of the leading causes of cancer death globally, and the majority of cases trace back to chronic hepatitis B or C infection. A failure to eliminate hepatitis now is, in a very real sense, a commitment to elevated liver cancer mortality well into the 2040s and 2050s.

There is also a systems feedback loop worth watching. As hepatitis C treatment scales up in higher-income settings and among easier-to-reach populations, the remaining undiagnosed and untreated cases become increasingly concentrated among marginalized groups: people who inject drugs, incarcerated populations, undocumented migrants. Reaching those groups requires not just medical tools but legal and social reforms that many governments are reluctant to pursue. The closer the world gets to elimination, the harder the remaining work becomes, and the more it demands confronting stigma and criminalization rather than simply distributing pills.

The 2030 deadline was always ambitious. Whether it functions as a genuine forcing mechanism or quietly becomes another aspirational target that the global health community politely moves past will depend on decisions being made right now about financing, political commitment, and whose lives are treated as worth the effort.